Janssen Submits Application Seeking FDA Approval of STELARA(R) (Ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis

HORSHAM, Pa., Dec. 16, 2016 -- (Healthcare Sales & Marketing Network) -- Janssen Biotech, Inc. (Janssen) announced today the submission of a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval ... Biopharmaceuticals, Dermatology, FDA Janssen, STELARA, ustekinumab, Psoriasis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news